Nottingham Digestive Disease Centre
Nottingham, Nottinghamshire, NG7 2UH, United Kingdom
NCT Number: NCT06551948
The investigators plan to measure the local (in vivo) production of hydrogen when methylcellulose is ingested, to see if the investigators can show a shift of the site of fermentation to the distal colon.
The investigators will achieve this using the Atmo pill, a recently developed ingestible gas-sensing wireless capsule manufactured by Atmo Biosciences. The pill is very similar in appearance and dimensions (26·8 mm long by 11·7 mm in diameter) to the Smart Pill, an FDA approved wireless capsule which measures local pH, which has been widely and safely used for over a decade. The Smart Pill is recommended for transit measurement by the American ACG Clinical Guidelines on Gastroparesis 3. The Atmo pill differs from the Smart Pill in measuring hydrogen and carbon dioxide within the colonic lumen rather than pH. The pill emits a radio signal to a small device worn by the participant to record the measurements periodically 4.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Nottingham, Nottinghamshire, NG7 2UH, United Kingdom
Aim
This pilot study aims to test the hypothesis that a gel of either methylcellulose or psyllium incorporating inulin will delay colonic fermentation compared to inulin combined with placebo (maltodextrin), resulting in an increase in colonic hydrogen concentration in the distal colon as measured by the Atmo pill.
Objective
The primary objective of this pilot is to quantify in vivo the hydrogen gas produced from colonic fermentation post ingestion. Previous studies have measured hydrogen concentration from breath analysis to infer colonic fermentation progression, however the Atmo pill will allow for direct measurement throughout colonic transit. By dividing the mean colonic hydrogen gas production into time quartiles, the investigators can better associate which region of the colon the fermentation is taking place (i.e., 4th quartile to represent distal colon region).
Secondary Objectives
Mean colonic hydrogen% in each quarter of colonic transit.
Mean colonic carbon dioxide% in each quarter of colonic transit.
Colon transit time (CTT) determined from Atmo pill.
Small bowel transit time (SBTT) of Atmo pill to caecum.
Area under curve (AUC) of breath hydrogen and methane for period 0 - 24hr.
Orocecal transit time (OCTT) from breath analysis.
Whole gut transit time assessed by blue muffin test.
Gas production over 48 hours incubation in vitro model of colon using participants stool samples (in collaboration with Quadram Institute).
Metabolite production (short chain fatty acids) using same in vitro model of colon (in collaboration with Quadram Institute).
Analysis of microbiota in participants stool using 16sRNA gene (in collaboration with Quadram Institute).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
15 g psyllium
15 gm methylcellulose
15 g maltodextrin
15g inulin
Time frame: up to 4 days
mean hydrogen as % of colonic gas during the 4 quarters of colonic transit
Time frame: up to 4 days
carbon dioxide as % of colonic gas from colonic fermentation post-ingestion of fibre gel drink ll over each quartile of colonic transit (AUC Q1, Q2, Q3, Q4)
Time frame: 0-6 hours
Area under curve (AUC) from time 0-6 hours of breath hydrogen (ppm.hours)
Time frame: up to 4 days
University of Nottingham
Other
RandomisEd PlAcebo ControlLed TrIal of MethylceILulose or PSyllium on FermentaTion of Inulin Assessed Using a Gas Sensing Capsule (REALISTIC)
Acronym: REALISTIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06687720
Colonic Diseases, Colonic Diseases, Functional
Ahmedabad, Gujarat, India
View Trial DetailsNCT07722572
Anxiety Disorders, Colonic Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT02136745
Colonic Diseases, Colonic Diseases, Functional
Boston, Massachusetts, United States
View Trial DetailsNCT06268717
Abdominal Pain, Alpha-Gal Syndrome
Chapel Hill, North Carolina, United States
View Trial Details